Antengene Launches Innovative ADC and TCE Programs at AACR 2026 Conference

Innovative Cancer Therapies at AACR 2026

Antengene Corporation Limited, a prominent global biotechnology firm publicly traded on the Hong Kong Stock Exchange (SEHK: 6996.HK), recently made headlines at the 2026 American Association for Cancer Research (AACR) Annual Meeting. There, the company unveiled three novel programs that are poised to make significant impacts on cancer treatment.

The Highlights of Antengene's Presentation

The company featured critical advancements including the presentation of ATG-125, a bispecific antibody-drug conjugate (ADC), along with two investigational T cell engagers (TCEs) denoted as ATG-106 and ATG-112. Each target represents a distinct approach to tackling various solid tumors, showcasing Antengene's innovative AnTenGager® TCE platform which seeks to streamline the delivery of therapies to targeted cancer cells.

ATG-125: A Game-Changer in Cancer Therapy

ATG-125 is particularly striking as it is designed to dual-target B7-H3 and PD-L1, two critical immune checkpoints commonly associated with poor prognosis in multiple solid tumors. Its mechanism is anticipated to enhance anti-tumor immunity while facilitating direct tumor cell destruction.
In preclinical studies, ATG-125 showed robust internalization in cells expressing both B7-H3 and PD-L1. The data indicated significant tumor cell apoptosis and improved T-cell activation, showcasing the potential of this compound in overcoming current treatment resistance challenges that contribute to therapy failures. Moreover, in in vivo models, ATG-125 maintained substantial anti-tumor activity, further supporting its pursuit in clinical trials.

Advancements in T Cell Engagers: ATG-106 and ATG-112

Equally impressive are the new T cell engagers, ATG-106 and ATG-112, both of which were developed with a focus on lowering the risk of cytokine release syndrome (CRS) while maintaining potent anti-tumor efficacy. ATG-106 targets CDH6, a marker overexpressed in ovarian and kidney cancers, and demonstrates a promising dichotomy of potent tumor-cytotoxicity coupled with limited T cell binding in the absence of target cells, alleviating a common safety concern in bispecific TCEs. This approach has resulted in complete remissions in early models, encouraging further exploration into its therapeutic application.

Similarly, ATG-112 centers on placental alkaline phosphatase (ALPP/G) and related isoforms, which are largely absent from healthy adult tissue but found in various cancers. Early results suggest that ATG-112 promotes selective tumor cell elimination with minimal impact on normal cells, thus providing a favorable safety profile for continued development.

A Vision for the Future

With a robust pipeline of over 30 investigational new drugs approved across different regions and multiple compounds on the brink of clinical study, Antengene is carving a niche in the oncology space. Their corporate mission—focused on developing best-in-class therapies for unmet medical needs—aligns with the broader vision of enhancing patient outcomes through innovation in cancer treatment.

In conclusion, the revelations shared at AACR 2026 solidify Antengene's role as a leader in biopharmaceutical innovation, promising to deliver next-generation therapies that could change the landscape of cancer treatment.

For further inquiries about Antengene's developments or to follow their journey in precision oncology, visit their official channels.